Proprietary LNA Chemistry

Santaris Pharma a/s owns, or exclusively licenses on a world-wide basis, all therapeutics rights to the basic LNA chemistry and a vast array of analogues thereof. These composition-of-matter patents provide the Company with the dominant position in LNA-based therapeutics. 

In addition to these core chemistry patents, Santaris Pharma owns or controls patents/patent applications covering the synthesis of LNA building blocks and key intermediates, therapeutic uses in humans and animals, optimal drug designs and drug formats, and patents/patent applications directed to individual compounds under development.

In total, Santaris Pharma owns or controls more than 53 different patent families, the sum of which provides the Company with exceptional and long-lived intellectual property coverage, ensuring both control of the LNA chemistry and freedom to operate in the exciting new field of RNA targeted drugs. This patent position was strengthened in 2008 with important new grants and the filings of more than 14 new applications.